Retroviral transduction using poloxamers
OwnerNatasa Anastasov, Ines Hofig +1inventors
InventorsNatasa Anastasov, Ines Hofig, Christian Thirion
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for transducing a target cell, the method comprising the step of contacting a target cell with a retroviral vector and a poloxamer having a molecular weight of 12.8 kDa to about 15 kDa. Further, the invention relates to the use of a poloxamer as defined herein, optionally in combination with a polycationic substance as defined herein, for transducing a target cell with a retroviral vector and a kit comprising a retroviral vector, a poloxamer as defined herein and, optionally, instructions for use.
Claims9
A method of gene therapy comprising:
- (i) transducing a target cell, said transducing comprising contacting the target cell in vitro or ex vivo with a retroviral vector and a poloxamer, said poloxamer having an average molecular weight of 12.8 kDa to about 15 kDa, wherein “about” refers to—10% to +20% of said average molecular weight, and said poloxamer having the formula HO(C2H4O)x(C3H6O)z(C2H4O)yH, wherein the average value of z is at least 43, and the average value of x+y is at least 230, and wherein said poloxamer is in a fluid state during the contacting step, wherein after said contacting step said retroviral vector enters said cell, and
- (ii) using the transduced cell for a gene therapy application.
A method of gene therapy comprising:
- (i) transducing a target cell, said transducing comprising contacting the target cell in vitro or ex vivo with a retroviral vector and a poloxamer, said poloxamer having an average molecular weight of 12.8 kDa to about 15 kDa, wherein “about” refers to—10% to +20% of said average molecular weight, and said poloxamer having the formula HO(C2H4O)x(C3H6O)z(C2H4O)yH, wherein the average value of z is at least 43, and the average value of x+y is at least 230, and wherein said poloxamer is in a fluid state during the contacting step, wherein after said contacting step said retroviral vector enters said cell, wherein said target cell is not brought into contact with one or more polycationic substances selected from the group of polycationic polymers of and polycationic peptides, and
- (ii) using the transduced cell for a gene therapy application.
Dependencies are inferred from the claim text.